Casdin Capital

LetsGetChecked is a healthcare technology company that facilitates at-home health testing. It connects users with regulated laboratories worldwide for various tests, including general wellness, sexual health, women's health, men's health, and COVID-19. Users collect samples at home using provided kits and mail them back for analysis; results are then accessible online. The platform aims to empower individuals to proactively manage their health, offering services across the United States, Canada, and Europe.

InnoSIGN specializes in mRNA-based pathway activity profiling technology, aimed at advancing precision medicine by offering deeper insights into disease mechanisms. The company leverages a comprehensive library of pathway activity profiles to enhance diagnostics and facilitate drug discovery. It provides researchers with quantitative PCR (qPCR) tests designed for decentralized use, which are available through a service testing facility located in the Netherlands. Through its innovative approach, InnoSIGN seeks to transform the understanding and treatment of various diseases.

Deepcell, Inc. is a biotechnology company based in Mountain View, California, that specializes in providing advanced diagnostic solutions through its innovative microfluidic imaging platform. Founded in 2015, the company focuses on delivering non-invasive tests with diagnostic-level accuracy, enabling researchers and clinicians to gain insights at the single-cell level. Deepcell's technology employs artificial intelligence to analyze and classify cells based on their morphological features, isolating viable cells for various applications in translational research, diagnostic testing, and therapeutics. By utilizing ordinary blood samples, Deepcell enhances the understanding of genetic health without the need for invasive procedures, thereby improving the diagnosis and treatment of diseases.

Standard BioTools, previously known as Fluidigm, is driven by a bold vision – unleashing tools to accelerate breakthroughs in human health. Standard BioTools has an established portfolio of essential, standardized next-generation technologies that help biomedical researchers develop medicines faster and better. As a leading solutions provider, the Company provides reliable and repeatable insights in health and disease using its proprietary mass cytometry and microfluidics technologies that help transform scientific discoveries into better patient outcomes. Standard BioTools works with leading academic, government, pharmaceutical, biotechnology, plant and animal research, and clinical laboratories worldwide, focusing on the most pressing needs in translational and clinical research, including oncology, immunology, and immunotherapy.

Verana Health, Inc. is a digital health company based in San Francisco, California, that specializes in transforming healthcare data into actionable insights. Founded in 2008 and formerly known as Digisight Technologies, the company connects healthcare providers with patients through innovative solutions. Its flagship product, SightBook, is a mobile application that enables users to test their vision and share results with their physicians in real-time, facilitating timely appointments and treatments. Verana Health manages data from over 20,000 healthcare providers and 70 electronic health record systems, leveraging its AI-enhanced platform, VeraQ™, to create a robust healthcare data ecosystem. By utilizing advanced analytics on curated datasets, Verana Health supports life sciences partners in improving clinical research and enhancing patient care outcomes.

Apella is an artificial intelligence startup focused on enhancing surgical procedures through advanced healthcare technology. Founded in 2019 and headquartered in San Francisco, California, the company develops systems that utilize AI, computer vision, and modern communication to digitize operating rooms. By collecting data from these environments via sensors, Apella analyzes the information to provide insights that can improve surgical quality, streamline operations, and aid in training and real-time decision-making for medical staff. Its innovative approach aims to elevate surgery outcomes and optimize the overall efficiency of healthcare delivery.

Exai Bio is a next-generation liquid biopsy company that specializes in the early and accurate diagnosis of cancer. The company has developed a proprietary platform that analyzes cell-free RNA profiles, utilizing advanced artificial intelligence and machine learning algorithms. This technology focuses on orphan non-coding RNA and small RNA sequences that are prevalent in tumors but absent in normal tissue. By delivering clinical insights into cancer biology, Exai Bio's platform aids healthcare professionals in identifying cancer at its earliest stages and informs personalized treatment options for patients.

Lunit Inc. is a medical AI software company based in Seoul, South Korea, specializing in advanced algorithms for medical image analysis and general object detection. The company focuses on developing solutions that aid physicians in making objective diagnoses through machine learning technology. Lunit's expertise encompasses various medical imaging fields, including digital chest X-ray, digital mammography, digital pathology, and fundus photography. The company's products include Lunit INSIGHT CXR for chest X-rays, Lunit INSIGHT MMG for mammography, and Lunit SCOPE, which provides AI-powered biomarkers for immuno-oncology. Lunit aims to enhance clinical decision-making by leveraging data-driven imaging biomarker technology, ultimately improving the accuracy and efficiency of cancer care. The effectiveness of Lunit's deep learning technology has been validated through its recognition in major image recognition competitions, showcasing its capacity to process complex medical imaging data.

Beacon Biosignals is a company focused on enhancing human health through the application of artificial intelligence in the analysis of brain activity. It has developed a platform that provides rapid and accurate electroencephalogram (EEG) reports, streamlining the diagnostic process by eliminating the need for adjudication and utilizing improved criteria for inclusion and exclusion. The platform captures real-time brain activity, supporting healthcare professionals in the study of neurological and psychiatric disorders. By enabling more precise quantification of treatment plans and helping identify optimal patient populations, Beacon Biosignals aims to facilitate targeted interventions and advance the field of brain analytics.

Loop Medical, backed by Cerba Healthcare and the Bill & Melinda Gates Foundation, is developing a painless, needleless blood collection device. This modular, cartridge-based system maintains sample quality, integrates with standard lab processes, and aims to make blood collection more accessible and convenient for patients and healthcare professionals.

23andMe, Inc. is a consumer genetics and research company headquartered in Sunnyvale, California, founded in 2006. It specializes in providing direct-to-consumer personal genome services through home-based saliva collection kits. The company offers a range of services, including Health + Ancestry, which provides insights into ancestry, traits, and health, and Ancestry + Traits, which details ancestry breakdown and various trait reports. 23andMe aims to help individuals understand their genetic makeup, enabling users to explore their ancestry, genealogy, and inherited traits. Additionally, the company markets its services to researchers and scientists, offering categorized and searchable genetic data. With a focus on consumer and research services, 23andMe is positioned within the rapidly growing biotech and healthcare sectors, contributing to the understanding of genetics and its implications for health.

Nautilus Biotechnology is a development-stage life sciences company focused on advancing proteomics, the study of proteins and their functions, to enhance therapeutic development and medical diagnostics. The company has created a platform technology that aims to quantify and unravel the complexities of the human proteome. Its flagship product, the Proteomic Analysis System, is a prototype single-molecule instrument designed to facilitate these efforts. The team at Nautilus comprises experts from various disciplines, including protein chemistry, molecular biology, and data science, enabling a multifaceted approach to overcoming challenges in the field. By harnessing this diverse expertise, Nautilus aims to revolutionize drug development and improve healthcare management through personalized and predictive medicine.

LetsGetChecked is a healthcare technology company that facilitates at-home health testing. It connects users with regulated laboratories worldwide for various tests, including general wellness, sexual health, women's health, men's health, and COVID-19. Users collect samples at home using provided kits and mail them back for analysis; results are then accessible online. The platform aims to empower individuals to proactively manage their health, offering services across the United States, Canada, and Europe.

C2i Genomics, Inc. specializes in whole genome analysis solutions aimed at monitoring tumor recurrence in post-surgery cancer patients. The company offers liquid biopsy services that analyze subtle changes in tumor DNA to provide insights into cancer progression and recurrence. This technology enables the development of a bio-platform approach applicable across various cancer types, facilitating the guidance of diverse treatment modalities, including surgery, chemotherapy, immunotherapy, and targeted therapies. Additionally, C2i Genomics provides cloud-based cancer diagnostic services to pharmaceutical and diagnostic organizations, enhancing the ability of healthcare providers to monitor treatment responses and detect recurrences or failures earlier than traditional methods allow. Founded in 2019 and headquartered in New York, with a research and development center in Haifa, Israel, C2i Genomics aims to improve the lives and outcomes of cancer patients through innovative diagnostic solutions.

Komodo Health Inc. is a healthcare technology company that develops a platform designed to enhance transparency and intelligence in the healthcare sector. Founded in 2014 and headquartered in New York, with an additional office in San Francisco, the company offers a suite of software applications, including its Healthcare Map, which tracks patient outcomes throughout the healthcare system. Its solutions, such as Aperture and Pulse, leverage advanced data science techniques to provide real-time insights and alerts on clinical information, while Serenity analyzes patient cohorts for deeper understanding. By serving various stakeholders, including life sciences companies, healthcare payers, and providers, Komodo Health aims to foster a more efficient and value-driven healthcare ecosystem through comprehensive patient-level insights.

Imagen enables Primary Care providers to become technology-enabled multispecialty practices, powering a successful transition from fee-for-service to value-based care. Its comprehensive platform includes in-office diagnostic testing, diagnostic interpretations powered by proprietary FDA-cleared machine learning software, and virtual specialist consults. Its platform empowers Primary Care providers to achieve healthcare’s quadruple aim of increasing quality, lowering costs, and improving the patient and provider experience.

Paige, founded in 2017 by Thomas Fuchs and colleagues from Memorial Sloan Kettering Cancer Center, specializes in computational pathology products that enhance cancer diagnostics. The company has developed a platform utilizing advanced deep learning algorithms to improve diagnostic stratification and cancer detection, particularly for breast and prostate cancers. This innovative technology aims to empower patients and their care teams to make informed treatment decisions by providing pathologists with critical insights for more accurate diagnoses. Paige's user-friendly platform minimizes the burden on IT resources while ensuring patient safety and data privacy. As a pioneer in the field, Paige has achieved FDA breakthrough designation for its computational pathology products, positioning itself at the forefront of transforming pathology workflows and increasing diagnostic confidence.

Oxford Nanopore Technologies is a biotechnology company specializing in nanopore-based sequencing technology for analyzing DNA, RNA, proteins, and small molecules. Its diverse product line includes the portable MinION device, the benchtop PromethION, the GridION system, and Flongle, which caters to on-demand sequencing needs. The technology enables real-time data streaming and is applicable across various fields such as human genomics, cancer research, microbiology, plant science, and environmental studies. Additionally, Oxford Nanopore's products support rapid and accessible molecular analysis, making them suitable for both laboratory and field use. The company's innovations are backed by a robust patent portfolio and are utilized in over 80 countries, addressing needs in healthcare, agriculture, and education. Founded in 2005 and headquartered in Oxford, United Kingdom, Oxford Nanopore also maintains offices in several other countries, enhancing its global reach in advancing genomic research and applications.

Lyra Health operates a digital health platform that enhances mental health care for employees by connecting them with a curated network of therapists and coaches. Founded in 2015 and based in Burlingame, California, Lyra uses matching technology to pair individuals with suitable providers based on their needs and preferences. The platform offers live video therapy, coaching, and digital self-care tools, ensuring faster access to care and better outcomes compared to traditional plans. Lyra assesses treatment effectiveness using clinical measures like the PHQ-9 and GAD-7 for conditions such as anxiety and depression. This approach results in significantly more people receiving care and achieving improved mental health outcomes.

GeneMatters is a provider of genetic counseling services aimed at enhancing patient access to genetic insights through a scalable telehealth platform. Established in 2016 and based in Minneapolis, Minnesota, the company operates an online genetic counseling network that offers pre-test and full-service genetic counseling, as well as caregiving services. By collaborating with hospitals, health networks, clinics, academic research centers, and genetic testing labs, GeneMatters facilitates a better understanding of genetic family history, allowing users to make informed decisions based on their genetic tests. The company’s services are designed to integrate seamlessly with existing patient workflows, ensuring flexible staffing and clinical expertise are readily available.

C2i Genomics, Inc. specializes in whole genome analysis solutions aimed at monitoring tumor recurrence in post-surgery cancer patients. The company offers liquid biopsy services that analyze subtle changes in tumor DNA to provide insights into cancer progression and recurrence. This technology enables the development of a bio-platform approach applicable across various cancer types, facilitating the guidance of diverse treatment modalities, including surgery, chemotherapy, immunotherapy, and targeted therapies. Additionally, C2i Genomics provides cloud-based cancer diagnostic services to pharmaceutical and diagnostic organizations, enhancing the ability of healthcare providers to monitor treatment responses and detect recurrences or failures earlier than traditional methods allow. Founded in 2019 and headquartered in New York, with a research and development center in Haifa, Israel, C2i Genomics aims to improve the lives and outcomes of cancer patients through innovative diagnostic solutions.

Lyra Health operates a digital health platform that enhances mental health care for employees by connecting them with a curated network of therapists and coaches. Founded in 2015 and based in Burlingame, California, Lyra uses matching technology to pair individuals with suitable providers based on their needs and preferences. The platform offers live video therapy, coaching, and digital self-care tools, ensuring faster access to care and better outcomes compared to traditional plans. Lyra assesses treatment effectiveness using clinical measures like the PHQ-9 and GAD-7 for conditions such as anxiety and depression. This approach results in significantly more people receiving care and achieving improved mental health outcomes.

Verana Health, Inc. is a digital health company based in San Francisco, California, that specializes in transforming healthcare data into actionable insights. Founded in 2008 and formerly known as Digisight Technologies, the company connects healthcare providers with patients through innovative solutions. Its flagship product, SightBook, is a mobile application that enables users to test their vision and share results with their physicians in real-time, facilitating timely appointments and treatments. Verana Health manages data from over 20,000 healthcare providers and 70 electronic health record systems, leveraging its AI-enhanced platform, VeraQ™, to create a robust healthcare data ecosystem. By utilizing advanced analytics on curated datasets, Verana Health supports life sciences partners in improving clinical research and enhancing patient care outcomes.

Genome Medical, Inc. is a genomic medicine delivery company based in South San Francisco, California, established in 2016. It operates a technology platform known as Genome Care Delivery, which connects individuals and healthcare providers with genetic specialists to facilitate virtual genetic consultations. The company focuses on various areas of clinical care, including cancer, cardiovascular health, reproductive health, pediatrics, and pharmacogenomics. By providing expert genetic assessments and personalized clinical action plans, Genome Medical helps patients understand their genetic risks and make informed treatment decisions. Additionally, the company supports healthcare providers in navigating the growing field of genetics, enhancing disease diagnosis, and improving patient care while aiming to reduce overall healthcare costs.

Thrive Earlier Detection Corp. is a healthcare company that specializes in developing advanced blood testing technologies for early cancer detection. Its flagship product, CancerSEEK, is a liquid biopsy test that analyzes genomic mutations in tumor DNA and protein markers in plasma, allowing for the identification of various cancers at their nascent stages, often before symptoms manifest. Founded in 2018 and headquartered in Cambridge, Massachusetts, with an additional office in Baltimore, Maryland, Thrive aims to integrate cancer screening into standard medical practice. The company leverages real-world data and machine learning to enhance the accuracy of cancer detection, facilitate follow-up testing, and streamline the transition to oncological care. Thrive operates as a subsidiary of Exact Sciences Corporation and has received investments from notable firms including Third Rock Ventures and Section 32.

Prominex, Inc. specializes in the development and manufacturing of molecular diagnostic assays for Point-of-Care (POC) infectious disease testing. Founded in 2016 and based in San Diego, California, the company has created the Validex System, which allows for the development of diagnostic assays without the need for complex thermal cycling or microfluidics. This innovative system works with crude clinical samples and eliminates the requirement for various laboratory components. Prominex aims to enhance access to low-cost, rapid diagnostic testing, particularly for sexually transmitted infections and respiratory diseases. Their upcoming SARS-CoV-2 test promises to deliver accurate results in just five minutes, empowering healthcare practitioners to make timely and informed decisions regarding treatment and infection management.

Imagen enables Primary Care providers to become technology-enabled multispecialty practices, powering a successful transition from fee-for-service to value-based care. Its comprehensive platform includes in-office diagnostic testing, diagnostic interpretations powered by proprietary FDA-cleared machine learning software, and virtual specialist consults. Its platform empowers Primary Care providers to achieve healthcare’s quadruple aim of increasing quality, lowering costs, and improving the patient and provider experience.

Lyra Health operates a digital health platform that enhances mental health care for employees by connecting them with a curated network of therapists and coaches. Founded in 2015 and based in Burlingame, California, Lyra uses matching technology to pair individuals with suitable providers based on their needs and preferences. The platform offers live video therapy, coaching, and digital self-care tools, ensuring faster access to care and better outcomes compared to traditional plans. Lyra assesses treatment effectiveness using clinical measures like the PHQ-9 and GAD-7 for conditions such as anxiety and depression. This approach results in significantly more people receiving care and achieving improved mental health outcomes.

GenapSys, Inc. develops innovative DNA sequencing technologies aimed at enhancing applied genomic testing and medical sequencing. Its primary product, the GenapSys Sequencer, utilizes a proprietary electrical-based detection method for single nucleotide incorporations, making it suitable for a wide range of applications, including research, gene editing, drug development, agriculture, forensics, and food testing. The sequencer is designed for versatility, allowing it to operate in various lab environments and automate clonal amplification. GenapSys is also focused on collaborating with local health agencies and researchers to facilitate rapid sequencing capabilities that can aid in controlling outbreaks. Its compact design enables deployment in diverse locations, such as hospitals and public transport hubs, for efficient virus sample analysis. Founded in 2010 and headquartered in Redwood City, California, GenapSys is committed to providing accessible and precise genetic testing solutions.

23andMe, Inc. is a consumer genetics and research company headquartered in Sunnyvale, California, founded in 2006. It specializes in providing direct-to-consumer personal genome services through home-based saliva collection kits. The company offers a range of services, including Health + Ancestry, which provides insights into ancestry, traits, and health, and Ancestry + Traits, which details ancestry breakdown and various trait reports. 23andMe aims to help individuals understand their genetic makeup, enabling users to explore their ancestry, genealogy, and inherited traits. Additionally, the company markets its services to researchers and scientists, offering categorized and searchable genetic data. With a focus on consumer and research services, 23andMe is positioned within the rapidly growing biotech and healthcare sectors, contributing to the understanding of genetics and its implications for health.

Flatiron Health, Inc. is a healthcare technology company dedicated to enhancing cancer research and patient care through advanced data integration and analytics. The firm develops OncologyCloud, a comprehensive platform that consolidates disparate healthcare information systems to provide insights into patient populations. This platform enables cancer care providers and life sciences companies to analyze treatment patterns, monitor adherence to clinical guidelines, and facilitate real-time patient matching to clinical trials. Additionally, Flatiron offers OncoCloud, a software solution for community oncology practices, and tools like Flatiron Assist and OncoEMR, which support clinical decision-making and compliance with oncology care models. Established in 2012 and headquartered in New York, Flatiron Health collaborates with over 280 community cancer practices, prominent academic research centers, and leading oncology companies, positioning itself as a key player in the oncology data landscape. The company operates as a subsidiary of Roche Holding AG.

23andMe, Inc. is a consumer genetics and research company headquartered in Sunnyvale, California, founded in 2006. It specializes in providing direct-to-consumer personal genome services through home-based saliva collection kits. The company offers a range of services, including Health + Ancestry, which provides insights into ancestry, traits, and health, and Ancestry + Traits, which details ancestry breakdown and various trait reports. 23andMe aims to help individuals understand their genetic makeup, enabling users to explore their ancestry, genealogy, and inherited traits. Additionally, the company markets its services to researchers and scientists, offering categorized and searchable genetic data. With a focus on consumer and research services, 23andMe is positioned within the rapidly growing biotech and healthcare sectors, contributing to the understanding of genetics and its implications for health.

Invitae is a genetic information company focused on integrating genetic insights into everyday medical practice to enhance healthcare quality for a large population. The company specializes in genetic diagnostics for hereditary disorders, offering a comprehensive service that consolidates multiple genetic tests into a single platform. Invitae's offerings include assessments for genes linked to hereditary cancer, neurological disorders, cardiovascular conditions, pediatric issues, metabolic disorders, and other hereditary ailments. By providing high-quality testing with quicker turnaround times and competitive pricing, Invitae aims to make genetic testing more accessible and effective for patients and healthcare providers alike.

Foundation Medicine, Inc. is a biotechnology company based in Cambridge, Massachusetts, that specializes in providing molecular information products for cancer diagnosis and treatment. The company utilizes advanced genomic profiling technologies to analyze tumor specimens, enabling healthcare providers to gain insights into individual patients' cancer profiles. This information assists in optimizing treatment strategies, particularly for targeted therapies and immunotherapies. Foundation Medicine’s product offerings include FoundationOne for solid tumors, FoundationOne Heme for blood-based cancers, and various diagnostic assays to support clinical decision-making in oncology. The company also maintains a knowledgebase, FoundationCORE, to disseminate scientific advancements and strengthen collaborations within the oncology community. Foundation Medicine has established strategic partnerships with major pharmaceutical companies and research organizations to enhance precision medicine initiatives and develop companion diagnostics for specific therapies. Founded in 2009, Foundation Medicine operates as a subsidiary of Roche Holdings, Inc.